Kiora PharmaceuticalsKPRX
KPRX
About: Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Employees: 12
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
7.48% less ownership
Funds ownership: 49.47% [Q3] → 41.98% (-7.48%) [Q4]
16% less funds holding
Funds holding: 19 [Q3] → 16 (-3) [Q4]
23% less capital invested
Capital invested by funds: $5.38M [Q3] → $4.16M (-$1.21M) [Q4]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
258%
upside
Avg. target
$10
258%
upside
High target
$10
258%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 27% 1-year accuracy 46 / 173 met price target | 258%upside $10 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Neutral
Newsfile Corp
2 weeks ago
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M.
Neutral
Newsfile Corp
3 weeks ago
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation.
Neutral
Newsfile Corp
1 month ago
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
Neutral
Newsfile Corp
2 months ago
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
Neutral
Newsfile Corp
2 months ago
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings.
Neutral
Newsfile Corp
5 months ago
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa.
Neutral
Newsfile Corp
5 months ago
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with retinitis pigmentosa. The ABACUS-2 trial will be a 36 patient, multi-center, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa.
Neutral
Newsfile Corp
6 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).
Neutral
Newsfile Corp
8 months ago
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on its pipeline of therapeutics for the treatment of retinal diseases. During the quarter, Kiora finalized the trial design for the Phase 2 study (ABACUS-2) of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa through our partnership with Théa Open Innovation (TOI).
Neutral
Newsfile Corp
8 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast. On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D.
Charts implemented using Lightweight Charts™